查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1561427

2024-2032 年寵物癌症治療市場報告（按治療方法、動物物種、癌症類型、最終用戶和地區）

Pet Cancer Therapeutics Market Report by Therapy, Animal Species, Cancer Type, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 147 Pages | 商品交期: 2-3個工作天內

價格

2023年，全球寵物癌症治療市場規模達2.952IMARC Group美元。寵物擁有率的提高和人類與動物之間的聯繫、獸醫學和研究的進步以及人們對寵物癌症療法的可用性和益處的認知不斷提高是推動市場的一些主要因素。

寵物癌症療法是一種專門的醫療療法和藥物，旨在診斷、治療和控制動物（尤其是狗和貓）的癌症。與人類癌症治療類似，這些療法可能包括化療、放射治療、免疫療法、標靶治療和安寧療護。獸醫腫瘤學家使用這些療法來治療寵物的各種癌症並提高它們的生活品質。隨著獸醫學的不斷進步，寵物癌症療法的可用性和有效性不斷提高，使寵物主人能夠為他們心愛的被診斷患有癌症的動物夥伴獲得全面和富有同情心的護理。

由於寵物飼養量和人與動物關係的增加，寵物主人投資先進醫療（包括癌症治療）的意願不斷增強，以確保動物夥伴的福祉，這將刺激預測期內市場的成長。此外，由於診斷能力的提高和壽命的延長，寵物癌症盛行率不斷上升，增加了對有效和專業治療的需求。除此之外，獸醫腫瘤學和研究的許多進步，包括為寵物開發更有針對性和創新的癌症療法，促進了市場的成長。此外，寵物主人對寵物癌症治療的可用性和益處的認知不斷提高，導致了早期檢測和干涉，推動了市場成長。此外，專門獸醫腫瘤中心的建立以及獸醫和人類腫瘤學家之間不斷加強的合作，提高了寵物癌症護理的可及性和專業知識，也促進了市場的成長。

寵物癌症治療市場趨勢/促進因素：

增加寵物飼養量和人與動物的聯繫

寵物數量的增加和人類與動物關係的加強已成為寵物癌症治療市場的重要驅動力。隨著越來越多的家庭歡迎寵物進入他們的生活，這些伴侶動物被廣泛認為是珍貴的家庭成員。這種情感連結培養了寵物主人的深刻責任感，以確保毛茸茸的同伴的福祉和健康。因此，寵物主人越來越願意投資先進的癌症治療方法來對抗疾病並提高寵物的生活品質。寵物主人為他們的寵物尋求盡可能最好的護理，導致對有效的癌症治療方法的需求增加，這些治療方法可以減輕寵物的痛苦並延長寵物的生命。

獸醫腫瘤學的進展

近年來，由於技術進步和研究突破，獸醫腫瘤學領域取得了顯著進展。改進的診斷技術可以實現早期、準確的癌症檢測，使獸醫能夠及時啟動治療。此外，人們對寵物癌症生物學認知的提升為標靶治療、免疫療法和新型治療方式打開了大門。獸醫腫瘤學家現在擁有一個擴展的癌症治療工具箱，有助於制定適合每隻寵物獨特狀況的個人化護理計劃。這些進步為面臨癌症診斷的寵物主人帶來了希望，並鼓勵他們探索和選擇先進且有效的癌症療法。

不斷成長的獸醫醫療保健支出

人們對寵物的看法從單純的動物夥伴轉變為重要的家庭成員，導致獸醫醫療保健支出模式顯著轉變。今天的寵物主人比以往任何時候都更願意分配大量的財政資源來確保他們的寵物的健康和長壽。人們對現有癌症治療方案的認知不斷增強，以及對提供最佳護理的渴望，推動了寵物癌症治療支出的增加。主人願意投資最新、最有效的癌症治療方法來對抗這種疾病，並改善毛茸茸的同伴的整體健康和幸福感。獸醫醫療保健支出的激增進一步推動了寵物癌症治療市場的發展，為寵物先進癌症治療方案的研究、創新和開發創造了機會。

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球寵物癌症治療市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：透過療法

  • 化療
    • 市場趨勢
    • 市場預測
  • 放射治療
    • 市場趨勢
    • 市場預測
  • 免疫療法
    • 市場趨勢
    • 市場預測
  • 聯合療法
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 7 章：市場區隔：依動物種類

  • 貓
    • 市場趨勢
    • 市場預測
  • 狗
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 8 章：市場區隔：按癌症類型

  • 淋巴瘤
    • 市場趨勢
    • 市場預測
  • 肥大細胞癌
    • 市場趨勢
    • 市場預測
  • 黑色素瘤
    • 市場趨勢
    • 市場預測
  • 乳癌和鱗狀細胞癌
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 9 章：市場區隔：按最終用戶

  • 獸醫醫院和臨床藥房
    • 市場趨勢
    • 市場預測
  • 零售藥局
    • 市場趨勢
    • 市場預測
  • 網路藥局
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 10 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場細分：按國家/地區
    • 市場預測

第 11 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 12 章：價值鏈分析

第 13 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 14 章：價格分析

第15章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • AB Science
    • Boehringer Ingelheim International GmbH
    • Elanco Animal Health Incorporated
    • ELIAS Animal Health LLC
    • Karyopharm Therapeutics
    • Pfizer Inc.
    • Regeneus Ltd.
    • Rhizen Pharmaceuticals AG
    • Torigen Pharmaceuticals Inc.
    • VetDC Inc.
    • Virbac
    • Zoetis Inc.
Product Code: SR112024A4472

The global pet cancer therapeutics market size reached US$ 295.2 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 635.9 Million by 2032, exhibiting a growth rate (CAGR) of 8.5% during 2024-2032. The increasing pet ownership rates and human-animal bond, advancements in veterinary medicine and research, and growing awareness about the availability and benefits of pet cancer therapeutics are some of the major factors propelling the market.

Pet cancer therapeutics are specialized medical treatments and drugs designed to diagnose, treat, and manage cancer in animals, particularly in dogs and cats. Similar to cancer treatments in humans, these therapeutics may include chemotherapy, radiation therapy, immunotherapy, targeted therapies, and palliative care. Veterinary oncologists administer these therapies to address various types of cancer in pets and improve their quality of life. As advancements in veterinary medicine continue, the availability and effectiveness of pet cancer therapeutics have increased, allowing pet owners to access comprehensive and compassionate care for their beloved animal companions diagnosed with cancer.

The rising willingness among pet owners to invest in advanced medical treatments, including cancer therapeutics, to ensure the well-being of their animal companions due to the increasing pet ownership and human-animal bond, will stimulate the growth of the market during the forecast period. Moreover, the growing prevalence of cancer in pets, owing to improved diagnostic capabilities and prolonged lifespan has augmented the demand for effective and specialized treatments. Apart from this, numerous advancements in veterinary oncology and research, including the development of more targeted and innovative cancer therapies for pets, have catalyzed the market growth. Additionally, the heightening awareness among pet owners about the availability and benefits of pet cancer therapeutics has led to early detection and intervention, propelling the market growth. Furthermore, the establishment of specialized veterinary oncology centers and the rising collaborations between veterinary and human oncologists that improve the accessibility and expertise in pet cancer care are contributing to the market growth.

Pet Cancer Therapeutics Market Trends/Drivers:

Increasing pet ownership and human-animal bond

The rise in pet ownership and the strengthening human-animal bond have become significant drivers in the market for pet cancer therapeutics. As more households welcome pets into their lives, these companion animals are widely considered cherished family members. This emotional connection fosters a deep sense of responsibility among pet owners to ensure the well-being and health of their furry companions. Consequently, there is a growing willingness among pet owners to invest in advanced cancer treatments to combat the disease and enhance the quality of life for pets. Pet owners seek the best possible care for their pets, leading to an increased demand for effective cancer therapeutics that can alleviate suffering and prolong their pets' lives.

Advancements in veterinary oncology

The field of veterinary oncology has witnessed remarkable progress in recent years, owing to technological advancements and research breakthroughs. Improved diagnostic techniques enable early and accurate cancer detection, empowering veterinarians to initiate timely treatment. Moreover, the rise in understanding of cancer biology in pets has opened doors to targeted therapies, immunotherapies, and novel treatment modalities. Veterinary oncologists now have an expanded toolbox of cancer treatments, facilitating the development of personalized care plans tailored to each pet's unique condition. These advancements instill hope in pet owners facing a cancer diagnosis for their beloved animals and encourage them to explore and opt for advanced and effective cancer therapies.

Growing veterinary healthcare expenditure

The changing perception of pets from mere animal companions to valued family members has led to a notable shift in spending patterns on veterinary healthcare. Pet owners today are more willing than ever to allocate substantial financial resources to ensure their pets' well-being and longevity. The growing awareness of available cancer treatment options and the desire to provide the best possible care have driven the increase in expenditure on pet cancer therapeutics. Owners are willing to invest in the latest and most effective cancer treatments to combat the disease and improve the overall health and happiness of their furry companions. This surge in veterinary healthcare spending further propels the pet cancer therapeutics market, creating opportunities for research, innovation, and the development of advanced cancer treatment options for pets.

Pet Cancer Therapeutics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global pet cancer therapeutics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on therapy, animal species, cancer type and end user.

Breakup by Therapy:

  • Chemotherapy
  • Radiation Therapy
  • Immunotherapy
  • Combination Therapy
  • Others

Chemotherapy dominates the market

The report has provided a detailed breakup and analysis of the market based on the therapy. This includes chemotherapy, radiation therapy, immunotherapy, combination therapy, and others. According to the report, chemotherapy represented the largest segment.

Chemotherapy is widely used as a standard treatment for various types of pet cancers. As a potent and systematic approach, chemotherapy targets rapidly dividing cancer cells, inhibiting their growth and spread. Its ability to treat a wide range of cancers, including lymphoma, mast cell tumors, and osteosarcoma, makes it a versatile and essential therapeutic option for veterinary oncologists.

Moreover, advancements in veterinary medicine have led to the development of more targeted and less toxic chemotherapy regimens, reducing adverse effects and improving the overall quality of life for pets undergoing treatment. The increasing prevalence of pet cancer cases, coupled with the growing awareness among pet owners about available treatment options, further contributes to the expansion of the chemotherapy segment.

Breakup by Animal Species:

  • Cats
  • Dogs
  • Others

Dogs hold the largest share in the market

A detailed breakup and analysis of the market based on the animal species has also been provided in the report. This includes cats, dogs, and others. According to the report, dogs accounted for the largest market share.

Dogs have a higher susceptibility to various types of cancers, mirroring human conditions. As a popular companion animal, dogs are commonly affected by cancers such as lymphoma, melanoma, and mammary tumors, among others. The similarities in cancer biology and tumor types between dogs and humans make dogs valuable models for studying cancer treatments, leading to advancements in therapeutic approaches that benefit both species. Veterinary oncology research conducted in dogs has resulted in the development of targeted therapies, immunotherapies, and novel treatment modalities that can be translated to human medicine. Furthermore, the strong emotional bond between pet owners and their dogs fosters a willingness to invest in their healthcare, including cancer treatments, thus driving the demand for effective pet cancer therapeutics.

Breakup by Cancer Type:

  • Lymphoma
  • Mast Cell Cancer
  • Melanoma
  • Mammary and Squamous Cell Cancer
  • Others

Mast cell cancer represents the most popular type of cancer

The report has provided a detailed breakup and analysis of the market based on the cancer type. This includes lymphoma, mast cell cancer, melanoma, mammary and squamous cell cancer, and others. According to the report, mast cell cancer represented the largest segment.

Mast cell tumors are one of the most common skin cancers in dogs, affecting various breeds and age groups. Their diverse behavior and variable response to treatments necessitate specialized therapeutics for effective management. Veterinary oncologists are continually researching and developing targeted therapies and immunotherapies specifically tailored to combat mast cell cancer. As a result, advancements in pet cancer therapeutics for mast cell tumors benefit dogs as well as contribute to the broader understanding and treatment of mast cell-related conditions in humans. The increasing awareness among pet owners about the need for early detection and comprehensive treatment options further drives the demand for innovative and efficient pet cancer therapeutics.

Breakup by End User:

  • Veterinary Hospitals and Clinical Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Veterinary hospitals and clinical pharmacies account for the largest market share

The report has provided a detailed breakup and analysis of the market based on the end-user. This includes veterinary hospitals and clinical pharmacies, retail pharmacies, online pharmacies, and others. According to the report, veterinary hospitals and clinical pharmacies represented the largest segment.

Veterinary hospitals and clinical pharmacies play a crucial role in driving the pet cancer therapeutics market by serving as key distribution and treatment centers for specialized pet cancer drugs and therapies. These institutions provide a centralized platform for pet owners to access a wide range of cancer treatments, including chemotherapy agents, targeted therapies, and immunotherapies. Veterinary hospitals collaborate with pharmaceutical companies and research institutions to stay updated on the latest advancements in pet cancer therapeutics, offering cutting-edge treatment options to their patients. Clinical pharmacies within these facilities ensure accurate drug dispensing and administration, adhering to precise dosages and treatment protocols. Their expertise in handling pet cancer therapeutics and providing personalized care contributes to improved treatment outcomes and enhances pet owners' confidence in seeking optimal cancer care for their beloved animal companions, ultimately driving the growth of the pet cancer therapeutics market.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America exhibits a clear dominance in the market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and Others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and Others) Latin America (Brazil, Mexico and Others), Middle East and Africa. According to the report, North America accounted for the largest market share.

North America held the biggest share in the market since the region has a high prevalence of pet ownership, and there is a strong bond between pet owners and their animals, leading to a greater willingness to invest in their healthcare, including cancer treatment. North America is also at the forefront of advancements in veterinary medicine and oncology research, resulting in the development of innovative and targeted pet cancer therapeutics. Veterinary hospitals and research institutions in the region collaborate closely with pharmaceutical companies to conduct clinical trials and introduce cutting-edge treatments to the market. Additionally, the presence of well-established veterinary healthcare infrastructure and a growing trend of personalized pet care contribute to the demand for specialized and effective cancer therapies. These factors collectively drive the growth of the market for pet cancer therapeutics in North America, making it a leading region in the industry.

Competitive Landscape:

The market is experiencing steady growth in recent years as various key players are focusing on the development of targeted therapies and immunotherapies tailored to specific types of pet cancers, aiming to enhance treatment effectiveness and reduce side effects. Numerous advancements in precision medicine by leading players have led to the identification of genetic and molecular biomarkers, allowing for personalized treatment approaches. Additionally, novel drug delivery methods, such as nanoparticles and liposomes, are being explored by manufacturers to improve drug stability and enhance tumor penetration. The integration of emerging technologies like artificial intelligence (AI) and machine learning (ML) in pet cancer research is revolutionizing data analysis and accelerating drug discovery processes. We also expect the market to witness new entrants, consolidation of product portfolios, rise in research and development (R&D) initiatives, and increased strategic collaborations to drive healthy competition within the pet cancer therapeutics domain.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • AB Science
  • Boehringer Ingelheim International GmbH
  • Elanco Animal Health Incorporated
  • ELIAS Animal Health LLC
  • Karyopharm Therapeutics
  • Pfizer Inc.
  • Regeneus Ltd.
  • Rhizen Pharmaceuticals AG
  • Torigen Pharmaceuticals Inc.
  • VetDC Inc.
  • Virbac
  • Zoetis Inc.

Recent Developments:

  • In July 2023, Boehringer Ingelheim International GmbH, a leading pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for its innovative product, NexGard PLUS. This groundbreaking advancement in pet healthcare introduces a chewable tablet specifically designed to safeguard dogs from both internal and external parasites. The tablet contains a powerful combination of active ingredients, including afoxolaner, moxidectin, and pyrantel, which work synergistically to provide comprehensive protection against common parasitic threats.
  • In Dec 2022, Elanco Animal Health Incorporated, a prominent animal health company, announced a groundbreaking achievement with the FDA approval of Bexacat (bexagliflozin tablets). Bexacat marks a significant milestone as the first-of-its-kind oral treatment option for feline diabetes. This pioneering medication introduces a novel approach to managing diabetes in cats, addressing an unmet medical need in the veterinary industry. Bexacat, formulated as easily administered tablets, offers a promising solution for feline diabetes management, providing veterinarians and pet owners with an effective and convenient alternative to traditional insulin injections.
  • In Nov 2021, ELIAS Animal Health LLC, a leading biotechnology company specializing in cancer therapeutics for pets, announced a significant development in the field of oncolytic virotherapy. The company has successfully obtained an exclusive in-license from Genelux Corporation for their cutting-edge Oncolytic Vaccinia Virus Treatment. This groundbreaking treatment utilizes a modified vaccinia virus to target and destroy cancer cells in pet animals. By leveraging the virus's inherent ability to replicate and infect cancer cells while sparing healthy tissues, this therapy offers a novel approach to combat various types of pet cancers.

Key Questions Answered in This Report

  • 1. What was the size of the global pet cancer therapeutics market in 2023?
  • 2. What is the expected growth rate of the global pet cancer therapeutics market during 2024-2032?
  • 3. What are the key factors driving the global pet cancer therapeutics market?
  • 4. What has been the impact of COVID-19 on the global pet cancer therapeutics market?
  • 5. What is the breakup of the global pet cancer therapeutics market based on the therapy?
  • 6. What is the breakup of the global pet cancer therapeutics market based on thej animal species?
  • 7. What is the breakup of the global pet cancer therapeutics market based on cancer type?
  • 8. What is the breakup of the global pet cancer therapeutics market based on the end user?
  • 9. What are the key regions in the global pet cancer therapeutics market?
  • 10. Who are the key players/companies in the global pet cancer therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pet Cancer Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapy

  • 6.1 Chemotherapy
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Radiation Therapy
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Immunotherapy
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Combination Therapy
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Animal Species

  • 7.1 Cats
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Dogs
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Cancer Type

  • 8.1 Lymphoma
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Mast Cell Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Melanoma
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Mammary and Squamous Cell Cancer
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Veterinary Hospitals and Clinical Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 AB Science
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
    • 15.3.2 Boehringer Ingelheim International GmbH
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 SWOT Analysis
    • 15.3.3 Elanco Animal Health Incorporated
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
    • 15.3.4 ELIAS Animal Health LLC
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
    • 15.3.5 Karyopharm Therapeutics
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 Pfizer Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Regeneus Ltd.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
    • 15.3.8 Rhizen Pharmaceuticals AG
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Torigen Pharmaceuticals Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
    • 15.3.10 VetDC Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
    • 15.3.11 Virbac
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Zoetis Inc.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Pet Cancer Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Pet Cancer Therapeutics Market: Breakup by Therapy (in %), 2023
  • Figure 5: Global: Pet Cancer Therapeutics Market: Breakup by Animal Species (in %), 2023
  • Figure 6: Global: Pet Cancer Therapeutics Market: Breakup by Cancer Type (in %), 2023
  • Figure 7: Global: Pet Cancer Therapeutics Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Pet Cancer Therapeutics Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Pet Cancer Therapeutics (Chemotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Pet Cancer Therapeutics (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Pet Cancer Therapeutics (Radiation Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Pet Cancer Therapeutics (Radiation Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Pet Cancer Therapeutics (Immunotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Pet Cancer Therapeutics (Immunotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Pet Cancer Therapeutics (Combination Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Pet Cancer Therapeutics (Combination Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Pet Cancer Therapeutics (Other Therapies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Pet Cancer Therapeutics (Other Therapies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Pet Cancer Therapeutics (Cats) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Pet Cancer Therapeutics (Cats) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Pet Cancer Therapeutics (Dogs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Pet Cancer Therapeutics (Dogs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Pet Cancer Therapeutics (Other Animal Species) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Pet Cancer Therapeutics (Other Animal Species) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Pet Cancer Therapeutics (Lymphoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Pet Cancer Therapeutics (Lymphoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Pet Cancer Therapeutics (Mast Cell Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Pet Cancer Therapeutics (Mast Cell Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Pet Cancer Therapeutics (Melanoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Pet Cancer Therapeutics (Melanoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Pet Cancer Therapeutics (Mammary and Squamous Cell Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Pet Cancer Therapeutics (Mammary and Squamous Cell Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Pet Cancer Therapeutics (Other Cancer Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Pet Cancer Therapeutics (Other Cancer Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Pet Cancer Therapeutics (Veterinary Hospitals and Clinical Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Pet Cancer Therapeutics (Veterinary Hospitals and Clinical Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Pet Cancer Therapeutics (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Pet Cancer Therapeutics (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Global: Pet Cancer Therapeutics (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Global: Pet Cancer Therapeutics (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Global: Pet Cancer Therapeutics (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Global: Pet Cancer Therapeutics (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: North America: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: North America: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: United States: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: United States: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Canada: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Canada: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Asia-Pacific: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Asia-Pacific: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: China: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: China: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Japan: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Japan: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: India: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: India: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: South Korea: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: South Korea: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Australia: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Australia: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Indonesia: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Indonesia: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Others: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Others: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Europe: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Europe: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Germany: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Germany: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: France: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: France: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: United Kingdom: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: United Kingdom: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Italy: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Italy: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Spain: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Spain: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Russia: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Russia: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Others: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Others: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Latin America: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Latin America: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Brazil: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Brazil: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Mexico: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Mexico: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Others: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 88: Others: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 89: Middle East and Africa: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 90: Middle East and Africa: Pet Cancer Therapeutics Market: Breakup by Country (in %), 2023
  • Figure 91: Middle East and Africa: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 92: Global: Pet Cancer Therapeutics Industry: SWOT Analysis
  • Figure 93: Global: Pet Cancer Therapeutics Industry: Value Chain Analysis
  • Figure 94: Global: Pet Cancer Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pet Cancer Therapeutics Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Pet Cancer Therapeutics Market Forecast: Breakup by Therapy (in Million US$), 2024-2032
  • Table 3: Global: Pet Cancer Therapeutics Market Forecast: Breakup by Animal Species (in Million US$), 2024-2032
  • Table 4: Global: Pet Cancer Therapeutics Market Forecast: Breakup by Cancer Type (in Million US$), 2024-2032
  • Table 5: Global: Pet Cancer Therapeutics Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Pet Cancer Therapeutics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Pet Cancer Therapeutics Market: Competitive Structure
  • Table 8: Global: Pet Cancer Therapeutics Market: Key Players